盛德鑫泰(300881) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 312,898,642.33, a decrease of 2.14% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 18,464,276.16, an increase of 66.97% year-on-year[5] - The basic earnings per share for Q3 2022 was CNY 0.18, reflecting a growth of 63.64% compared to the previous year[5] - Total operating revenue for the period reached ¥887,232,060.10, an increase of 8.6% compared to ¥816,679,490.94 in the previous period[17] - Net profit for the period was ¥47,115,910.57, representing a 46.4% increase from ¥32,197,809.24 in the previous period[19] - The total comprehensive income for the period was CNY 47,115,910.57, compared to CNY 32,197,809.24 in the previous period, representing an increase of approximately 46.4%[20] - Basic and diluted earnings per share increased to CNY 0.47 from CNY 0.32, reflecting a growth of 46.9%[20] Assets and Liabilities - Total assets as of September 30, 2022, amounted to CNY 1,557,337,509.24, representing a 3.58% increase from the end of the previous year[5] - Current assets totaled ¥1,280,276,179.30, slightly up from ¥1,274,084,577.58 at the beginning of the year[15] - Total liabilities increased to ¥744,628,086.58 from ¥727,347,617.22, reflecting a growth of 2.9%[16] - The company's total assets reached ¥1,557,337,509.24, up from ¥1,503,441,128.71, indicating a growth of 3.6%[16] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 303,521,219.23, a decrease of 652.03% year-to-date[5] - The net cash flow from operating activities for the third quarter of 2022 was -303,521,219.23 RMB, a decrease of 652.03% compared to 54,983,093.86 RMB in the same period last year[9] - Cash inflow from operating activities totaled CNY 586,108,531.13, up from CNY 513,686,520.78, indicating an increase of about 14.1%[22] - Cash outflow from operating activities was CNY 889,629,750.36, compared to CNY 458,703,426.92 in the previous period, resulting in a net cash flow from operating activities of CNY -303,521,219.23[23] - The net cash flow from financing activities increased to 303,496,260.04 RMB, a significant increase of 763.19% from -45,762,877.73 RMB year-over-year[9] - Cash inflow from financing activities was CNY 397,314,545.15, compared to CNY 74,913,444.44 in the previous period, marking a substantial increase[23] - The net cash flow from financing activities was CNY 303,496,260.04, a turnaround from CNY -45,762,877.73 in the previous period[23] Inventory and Expenses - The company's inventory increased by 33.61% to CNY 281,184,945.24 due to a rise in raw material stock[8] - Total operating costs amounted to ¥830,913,427.91, up from ¥780,633,230.00, reflecting a rise of 6.4%[17] - Research and development expenses rose to ¥34,818,312.79, compared to ¥30,968,011.21, an increase of 12.0%[17] - The company's cash and cash equivalents decreased to ¥241,697,681.84 from ¥361,886,551.30, a decline of 33.2%[15] - Other income decreased by 68.79% to CNY 1,223,495.17, attributed to a reduction in government grants[8] - The company reported a significant increase in charitable donations, with other expenses rising by 577.89% to CNY 1,762,508.42[8] - The company reported a decrease in financial expenses to ¥5,756,675.99 from ¥6,386,571.96, a reduction of 9.8%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,598, with no preferred shareholders having restored voting rights[9] - Major shareholder Zhou Wenqing holds 43.50% of the shares, while another significant shareholder, Zong Huanqin, holds 20.25%[10] - The company has a total of 7 major shareholders with significant holdings, including a 7.85% stake held by Changzhou Lianhong Enterprise Management Center[10] - The company has a total of 1,500,000 restricted shares that were released from lock-up on September 1, 2022, as part of the initial public offering commitments[12] Investment Activities - The company holds stakes in several investment projects, including 0.3476% in Jiangsu Quanxin Biopharmaceutical Co., Ltd. and 5.1647% in Shenzhen Hertz Life Science Technology Co., Ltd.[13] - The company reported a significant increase in financing activities due to the non-fulfillment of conditions for terminating the recognition of receivable notes discounted[9] Other Information - The report was not audited, as stated in the third-quarter report[24] - The company has not disclosed any new product developments or market expansion strategies in the current report[11] - There are no preferred shareholders reported in the current financial statement[11]